Attitudes to antipsychotic drugs, and the quality of life of patients with schizophrenia
Keywords:
schizophrenia, attitudes towards medication, quality of lifeAbstract
There is no universal definition of the quality of life. Award proposed an interesting and clinically useful concept that the quality of life is the subject´s perception of interaction between severity of psychotic symptoms, side effects, including subjective responses to antipsychotic drugs and the level of psychosocial performance. Postneuroleptic dysphoria/negative attitudes towards drugs is one of the agents which have an influence on adherence and ultimately on outcome of the therapy. The aim of this study was analysis of relationships between subjective quality of life and negative attitudes towards drugs. Results show that negative attitudes towards drugs are correlated with lower quality of life.
References
1. The WHOQOL Group. The World Health Organization Quality of Life Assessment (the WHOOQOL) Soc. Sci. Med., 1995; 41: 1403-1409.
2. Award G., Voruganti L.P.N. Intervention Research in Psychosis: Issues Related to the assessment of Quality of Life. Schizophr. Bull., 2000; 26: 557-564.
3. Award G., Voruganti L.P.N., Heslegrave J. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation. Qual. Life Res., 1997; 6: 21-26.
4. Award A.G., Voruganti L.N.P. Neuroleptic dysphoria: Revisiting the concept 50 years later Acta Psychiatr. Scand., 2005; 111 (Supp 427): 6-13.
5. Voruganti L.N.P., Award A.G. Neuroleptic dysphoria:towards a new synthesis. Psychopathology, 2004; 171: 121-132.
6. Naber D., Moritz S., Lambert M. Improvement of schizophrenic patients subjective wellbeing under atypical antipsychotic drug. Schizophr. Res., 2001; 50: 79-80.
7. Voruganti L., Slomka P., Zabel P., Costa G, So A., Mattar A., Award AG: Subjective effects of AMPT-induced dopamine depletion in schizophrenia, the correlation between D2 binding ratio and dysphoric responces. Neuropsychopharmacology, 2001; 25; 642-650.
8. Verhoeff N.P., Christensen B.K., Hussey D., Lee M., Papatheodorou G., Kopala L. Effects of catecholamine depletion on D2 receptors binding motivation and attentiveness in human; a replication study. Pharmacol. Biochem. Behav., 2003; 74: 425-432.
9. Voruganti L., Heslegrave R.J., Award A.G. Neuroleptic dysphoria may be missing link between schizophrenia and substance abuse. J. Nerv. Ment. Dis., 1997; 185: 463-465.
10. Awad A.G. Subjective response to neuroleptics in schizophrenia. Schizophr. Bull., 1993; 19: 609-618.
11. Hogan T.P., Award A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenia: reliability and discriminative validity. Psychol. Med., 1983; 13: 177-183.
12. Murawiec S. Kwestionariusz postawy wobec leku – przedstawienie skali klinicznej. Postępy Psychiatrii i Neurologii, 1997; 6(3): 325-332.
13. Wilkinson G., Hesdon B., Wild D., Cookson R., Farina C., Sharma V., Fitzpatric R., Jenkinson C. Self-reported quality of life measure for the people with schizophrenia: the SQOS. Br. J Psychiatry, 2000; 177: 42-46A.
14. Fleischacker W.W., Meise U., Gunther V., et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr. Scand., 1994; 89(Suppl. 382): 511-515.
15. Awad A.G., Voruganti L.N.P., Heslegrave R.J. Assessment of the patient's subjective experiences in acute neuroleptic treatment: implications for compliance and outcome. Int. Clin. Psychopharmacol., 1996; 11(Suppl 2): 55-60.
16. Mohamed S., Rosenheck R., McEvoy J., Swarrtz M., Stroup S., Lieberman J.A. Cross-sectional and Longitudinal Relationships Between Insight and attitudes Toward Medication in Chronic schizophrenia. Schizophr. Bull., 2009; 35(2): 336-346.
17. Garavan J., Browne S., Gervin M., Lane A., Larkin C., O´Callahhen E. Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics, attitudes to medication and insights. Compr. Psychiatry, 1998; 39: 215-219.
18. Hoffer A., Kemmler G., Eder U., Edlinger M., Hummer M., Fleisch-hacker WW. Quality of life in schizophrenia: the impact of psychopatology, attitude toward medication and side effects. J. Clin. Psychiatry, 2004; 65(7): 932-939.
19. Puschner B., Born A., Giessler A., Helm H., Leese M., Bindman J.P., Gray R.J., Schene A., Kikkert M., Burti L., Marrella G., Becker T. Adherense of Medication and Quality of Life in People with Schizophrenia. Result of European Mulicenter Study. J. Nerv. Ment. Dis., 2006; 194(10): 746-752.
20. Day J., Bentall R.P., Roberts C., Randall f., Rogers A., Cattell D., Healy D., Rae P., Power C. Attitudes toward antipsychotic medication. The impact of clinical variables and relationships with health professionals. Arch. Gen. Psychiatry, 2005; 62: 717-724.
